Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction

Molecular Neurodegeneration

Volumn 10, Issue 1, 2015, Pages

  Vaden, Jada H ^a   Bhattacharyya, Bula J ^b   Chen, Ping Chung ^c   Watson, Jennifer A ^a   Marshall, Andrea G ^d   Phillips, Scott E ^a   Wilson, Julie A ^a   King, Gwendalyn D ^a   Miller, Richard J ^b   Wilson, Scott M ^a  

^a University of Alabama at Birmingham   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

JNK; K63 linked ubiquitin; MLK3; Motor endplate disease; Motor neuron; Neuromuscular junction; Synapse; Ubiquitin; Ubiquitin proteasome system; USP14

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MIXED LINEAGE KINASE 3; NEUROTRANSMITTER; PROTEASOME; PROTEINASE; STRESS ACTIVATED PROTEIN KINASE; UBIQUITIN SPECIFIC PROTEASE 14; UNCLASSIFIED DRUG; 1-(1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL)-2-PYRROLIDIN-1-YLETHANONE; ANTHRACENE DERIVATIVE; NERVE PROTEIN; PYRAZOLANTHRONE; PYRROLE DERIVATIVE; PYRROLIDINE DERIVATIVE; UBIQUITIN THIOLESTERASE; USP14 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; ENZYME INHIBITION; GENE EXPRESSION; INTRACELLULAR SIGNALING; LETHALITY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MOUSE MUTANT; MUSCLE MASS; MUSCLE STRENGTH; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; NONHUMAN; REGULATORY MECHANISM; SYNAPTIC TRANSMISSION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ATAXIA; BRAIN CORTEX; C57BL MOUSE; CATALYSIS; CELL CULTURE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FEMALE; GENETICS; HAND STRENGTH; MALE; NERVE CELL; NEUROMUSCULAR JUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN PROCESSING; ROTAROD TEST; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSGENE; TRANSGENIC MOUSE; ULTRASTRUCTURE;

MUS;

ANIMALS; ANTHRACENES; ATAXIA; CATALYSIS; CELLS, CULTURED; CEREBRAL CORTEX; EXPLORATORY BEHAVIOR; FEMALE; HAND STRENGTH; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; NERVE TISSUE PROTEINS; NEUROMUSCULAR JUNCTION; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PYRROLES; PYRROLIDINES; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; TRANSGENES; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 84928747278     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-10-3     Document Type: Article

References (38)

1. Kravtsova Ivantsiv Y, Sommer T, Ciechanover A: The lysine48-based polyubiquitin chain proteasomal signal: not a single child anymore. Angew Chem Int Ed Engl 2012, 52:192-8.
2. Welchman RL, Gordon C, Mayer RJ: Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005, 6:599-609. 10.1038/nrm1700
3. Lauwers E, Jacob C, Andre B: K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J Cell Biol 2009, 185:493-502. 10.1083/jcb.200810114
4. Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, Chen ZJ, et al.: IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Reports 2013, 3:724-33. 10.1016/j.celrep.2013.01.031
5. Schmukle AC, Walczak H: No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity. J Cell Sci 2012, 125:549-59. 10.1242/jcs.091793
6. Humphrey RK, Yu SM, Bellary A, Gonuguntla S, Yebra M, Jhala US: Lysine 63-linked ubiquitination modulates mixed lineage kinase-3 interaction with JIP1 scaffold protein in cytokine-induced pancreatic beta cell death. J Biol Chem 2013, 288:2428-40. 10.1074/jbc.M112.425884
7. Kraut DA, Prakash S, Matouschek A: To degrade or release: ubiquitin-chain remodeling. Trends Cell Biol 2007, 17:419-21. 10.1016/j.tcb.2007.06.008
8. Lee MJ, Lee BH, Hanna J, King RW, Finley D: Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzyme. Mol Cell Proteomics 2010, 10:R110-003871.
9. Anderson C, Crimmins S, Wilson JA, Korbel GA, Ploegh HL, Wilson SM: Loss of Usp14 results in reduced levels of ubiquitin in ataxia mice. J Neurochem 2005, 95:724-31. 10.1111/j.1471-4159.2005.03409.x
10. Hanna J, Hathaway NA, Tone Y, Crosas B, Elsasser S, Kirkpatrick DS, et al.: Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell 2006, 127:99-111. 10.1016/j.cell.2006.07.038
11. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, et al.: Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467:179-84. 10.1038/nature09299
12. Peth A, Besche HC, Goldberg AL: Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol Cell 2009, 36:794-804. 10.1016/j.molcel.2009.11.015
13. Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, et al.: A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014, 123:706-16. 10.1182/blood-2013-05-500033
14. D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, et al.: Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 2011, 17:1636-40. 10.1038/nm.2536
15. Jung H, Kim BG, Han WH, Lee JH, Cho JY, Park WS, et al.: Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling. Oncogenesis 2013, 2:e64. 10.1038/oncsis.2013.28
16. Lappe-Siefke C, Loebrich S, Hevers W, Waidmann OB, Schweizer M, Fehr S, et al.: The ataxia (axJ) mutation causes abnormal GABAA receptor turnover in mice. PLoS Genet 2009, 5:e1000631. 10.1371/journal.pgen.1000631
17. Lee BH, Finley D, King RW: A high-throughput screening method for identification of inhibitors of the deubiquitinating enzyme USP14. Curr Protoc Chem Biol 2012, 4:311-30.
18. Hyrskyluoto A, Bruelle C, Lundh SH, Do HT, Kivinen J, Rappou E, et al.: Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: involvement of the proteasome and ER stress-activated kinase IRE1alpha. Hum Mol Genet 2014, 23:5928-39. 10.1093/hmg/ddu317
19. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, et al.: Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 2014, 5:5453-71.
20. Wu N, Zhang C, Bai C, Han YP, Li Q: MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2014, 33:457-67. 10.1159/000358626
21. Wilson SM, Bhattacharyya B, Rachel RA, Coppola V, Tessarollo L, Householder DB, et al.: Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 2002, 32:420-5. 10.1038/ng1006
22. Crimmins S, Jin Y, Wheeler C, Huffman AK, Chapman C, Dobrunz LE, et al.: Transgenic rescue of ataxia mice with neuronal-specific expression of ubiquitin-specific protease 14. J Neurosci 2006, 26:11423-31. 10.1523/JNEUROSCI.3600-06.2006
23. Chen PC, Qin LN, Li XM, Walters BJ, Wilson JA, Mei L, et al.: The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J Neurosci 2009, 29:10909-19. 10.1523/JNEUROSCI.2635-09.2009
24. Chen PC, Bhattacharyya BJ, Hanna J, Minkel H, Wilson JA, Finley D, et al.: Ubiquitin homeostasis is critical for synaptic development and function. J Neurosci 2011, 31:17505-13. 10.1523/JNEUROSCI.2922-11.2011
25. Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL: A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J 2001, 20:5187-96. 10.1093/emboj/20.18.5187
26. Michler A, Sakmann B: Receptor stability and channel conversion in the subsynaptic membrane of the developing mammalian neuromuscular junction. Dev Biol 1980, 80:1-17. 10.1016/0012-1606(80)90494-7
27. Kues WA, Brenner HR, Sakmann B, Witzemann V: Local neurotrophic repression of gene transcripts encoding fetal AChRs at rat neuromuscular synapses. J Cell Biol 1995, 130:949-57. 10.1083/jcb.130.4.949
28. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, et al.: Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-8. 10.1038/nature06022
29. Ikeda F, Dikic I: Atypical ubiquitin chains: new molecular signals. 'Protein modifications: beyond the usual Suspects' review series. EMBO Rep 2008, 9:536-42. 10.1038/embor.2008.93
30. Jacobson AD, Zhang NY, Xu P, Han KJ, Noone S, Peng J, et al.: The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 s proteasome. J Biol Chem 2009, 284:35485-94. 10.1074/jbc.M109.052928
31. Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, et al.: Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009, 137:133-45. 10.1016/j.cell.2009.01.041
32. Drerup CM, Nechiporuk AV: JNK-interacting protein 3 mediates the retrograde transport of activated c-Jun N-terminal kinase and lysosomes. PLoS Genet 2013, 9:e1003303. 10.1371/journal.pgen.1003303
33. Collins CA, Wairkar YP, Johnson SL, DiAntonio A: Highwire restrains synaptic growth by attenuating a MAP kinase signal. Neuron 2006, 51:57-69. 10.1016/j.neuron.2006.05.026
34. Costello DA, Herron CE: The role of c-Jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus. Neuropharmacology 2004, 46:655-62. 10.1016/j.neuropharm.2003.11.016
35. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al.: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001, 98:13681-6. 10.1073/pnas.251194298
36. Zhang Y, Reckow S, Webhofer C, Boehme M, Gormanns P, Egge-Jacobsen WM, et al.: Proteome scale turnover analysis in live animals using stable isotope metabolic labeling. Anal Chem 2011, 83:1665-72. 10.1021/ac102755n
37. Moore CD, Thacker EE, Larimore J, Gaston D, Underwood A, Kearns B, et al.: The neuronal Arf GAP centaurin alpha1 modulates dendritic differentiation. J Cell Sci 2007, 120:2683-93. 10.1242/jcs.006346
38. King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, et al.: Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther J Am Soc Gene Ther 2011, 19:1793-801. 10.1038/mt.2011.77